Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ASP-2802 by Astellas Pharma for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...
ASP-2802 by Astellas Pharma for T-Cell Lymphomas: Likelihood of Approval
ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for T-Cell Lymphomas. According to GlobalData, Phase...
ASP-2802 by Astellas Pharma for Follicular Lymphoma: Likelihood of Approval
ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...
ASP-2802 by Astellas Pharma for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to...
ASP-2802 by Astellas Pharma for Marginal Zone B-cell Lymphoma: Likelihood of Approval
ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for Marginal Zone B-cell Lymphoma. According to...